As of 2025-07-16, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (64.41) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.59 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -1077.3%.
The range of the Relative Valuation is (53.78) - (75.23) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 23.9x | 18.2x |
| Forward P/E multiples | 14.3x - 20.1x | 16.2x |
| Fair Price | (53.78) - (75.23) | (64.41) |
| Upside | -916.0% - -1241.5% | -1077.3% |
| Date | P/E |
| 2025-07-11 | -1.75 |
| 2025-07-10 | -1.86 |
| 2025-07-09 | -1.90 |
| 2025-07-08 | -2.07 |
| 2025-07-07 | -2.04 |
| 2025-07-03 | -2.10 |
| 2025-07-02 | -2.13 |
| 2025-07-01 | -2.05 |
| 2025-06-30 | -2.02 |
| 2025-06-27 | -2.00 |
| 2025-06-26 | -2.00 |
| 2025-06-25 | -1.99 |
| 2025-06-24 | -1.95 |
| 2025-06-23 | -1.90 |
| 2025-06-20 | -1.91 |
| 2025-06-18 | -1.93 |
| 2025-06-17 | -1.88 |
| 2025-06-16 | -1.94 |
| 2025-06-13 | -2.00 |
| 2025-06-12 | -1.98 |
| 2025-06-11 | -2.12 |
| 2025-06-10 | -2.02 |
| 2025-06-09 | -2.00 |
| 2025-06-06 | -1.99 |
| 2025-06-05 | -1.92 |
| 2025-06-04 | -1.90 |
| 2025-06-03 | -1.92 |
| 2025-06-02 | -1.68 |
| 2025-05-30 | -1.58 |
| 2025-05-29 | -1.64 |
| 2025-05-28 | -1.57 |
| 2025-05-27 | -1.55 |
| 2025-05-23 | -1.55 |
| 2025-05-22 | -1.53 |
| 2025-05-21 | -1.54 |
| 2025-05-20 | -1.62 |
| 2025-05-19 | -1.59 |
| 2025-05-16 | -1.53 |
| 2025-05-15 | -1.43 |
| 2025-05-14 | -1.38 |
| 2025-05-13 | -1.39 |
| 2025-05-12 | -1.48 |
| 2025-05-09 | -1.41 |
| 2025-05-08 | -1.42 |
| 2025-05-07 | -1.35 |
| 2025-05-06 | -1.35 |
| 2025-05-05 | -1.45 |
| 2025-05-02 | -1.59 |
| 2025-05-01 | -1.61 |
| 2025-04-30 | -1.62 |